Quantcast
Home > Quotes > NBRV

Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) Quote & Summary Data

NBRV 
$1.98
*  
0.09
4.35%
Get NBRV Alerts
*Delayed - data as of Aug. 23, 2019  -  Find a broker to begin trading NBRV now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
7
Today's High / Low
$ 2.0701 / $ 1.95
Share Volume
2,174,965
50 Day Avg. Daily Volume
1,245,359
Previous Close
$ 2.07
52 Week High / Low
$ 3.27 / $ 1.12
Market Cap
145,255,592
P/E Ratio
NE
Forward P/E (1y)
NE
Earnings Per Share (EPS)
$ -1.90
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
0.81

Intraday Chart

Shares Traded

Share Volume:
2,174,965
50 Day Avg. Daily Volume:
1,245,359

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -1.90

Trading Range

The current last sale of $1.98 is 76.79% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 2.0701 $ 3.27
 Low: $ 1.95 $ 1.12

Company Description (as filed with the SEC)

We are a biopharmaceutical company engaged in the development of novel anti-infective agents to treat serious infections. We have two product candidates that have been submitted to the U.S. Food and Drug Administration, or the FDA, for approval: lefamulin, potentially the first pleuromutilin antibiotic available for oral and intravenous (or IV) administration in humans, for the treatment of community-acquired bacterial pneumonia, or CABP and CONTEPO, a potentially first-in-class epoxide antibiotic for IV use in the United States for complicated urinary tract infections, or cUTI. We may potentially develop lefamulin and CONTEPO for additional indications. Both lefamulin formulations and CONTEPO were granted Qualified Infectious Disease Product, or QIDP, and Fast Track designation by the FDA, enabling priority review of the New Drug Applications, or the NDAs by the FDA.  ... More ...  



Risk Grade

Where does NBRV fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 2.07
Open Date:
Aug. 23, 2019
Close Price:
$ 1.98
Close Date:
Aug. 23, 2019


Consensus Recommendation

Analyst Info